CMS Manual System

Pub. 100-04 Medicare Claims Processing

Department of Health & Human Services (DHHS)
Centers for Medicare & Medicaid Services (CMS)

Transmittal 136 **Date: APRIL 9, 2004**

CHANGE REQUEST 3169

I. SUMMARY OF CHANGES: Two new "WW" codes have been established to identify Xeloda.

NEW/REVISED MATERIAL - EFFECTIVE DATE: July 1, 2004
***IMPLEMENTATION DATE: July 6, 2004**

Disclaimer for manual changes only: The revision date and transmittal number apply to the red italicized material only. Any other material was previously published and remains unchanged. However, if this revision contains a table of contents, you will receive the new/revised information only, and not the entire table of contents.

II. CHANGES IN MANUAL INSTRUCTIONS:
(R = REVISED, N = NEW, D = DELETED)

R/N/D	CHAPTER/SECTION/SUBSECTION/TITLE
R	17/80.1.2/HCPCS and NDC Reporting for Prodrugs

***III. FUNDING:**

These instructions shall be implemented within your current operating budget.

IV. ATTACHMENTS:

	Business Requirements
X	**Manual Instruction**
	Confidential Requirements
	One-Time Notification
X	**Recurring Update Notification**

***Medicare contractors only**

80.1.2 - HCPCS and NDC Reporting for Prodrugs

(Rev. 136, 04-09-04)

FI claims

For oral anti-cancer Prodrugs HCPCS code J8999 is reported with revenue code 0636.

DMERC claims

The supplier reports the NDC code on the claim. The DMERC converts the NDC code to a "WW" HCPCS code for CWF. *As new "WW" codes are established for oral anti-cancer drugs they will be communicated in a Recurring Update Notification.*

Attachment – Recurring Update Notification

Pub. 100-04	Transmittal: 136	Date: April 9, 2004	Change Request 3169

SUBJECT: Addition of Two "WW" Codes to Identify Xeloda (Capecitabine)

I. GENERAL INFORMATION

A. Background: Suppliers are currently instructed to bill oral anti-cancer drugs to the DMERCs using the appropriate national drug code (NDC).

B. Policy: The addition of the following "WW" codes will allow the DMERCs to correctly adjudicate this oral anti-cancer drug. The proposed additions will read:

NDC	New Code	Dosing	Trade Name	Generic Name	FDA Approval of NDC
00004-1100-20	WW089	150 mg oral	Xeloda	Capecitabine	10/01/03
00004-1101-50	WW096	500 mg oral	Xeloda	Capecitabine	10/01/03

The approval date for Medicare coverage for the above drug is October 1, 2003.

****NOTE:** WW codes are for DMERC internal systems processing only and providers should still bill using the appropriate NDC codes for oral anti-cancer drugs.

C. Provider Education: None.

II. BUSINESS REQUIREMENTS

"Shall" denotes a mandatory requirement
"Should" denotes an optional requirement

Requirement #	Requirements	Responsibility
3169.1	DMERCs shall add WW089 and WW096 to their systems to adjudicate claims submitted for the NDCs listed above.	DMERCs

III. SUPPORTING INFORMATION & POSSIBLE DESIGN CONSIDERATIONS

A. Other Instructions: N/A

X-Ref Requirement #	Instructions

B. Design Considerations: N/A

X-Ref Requirement #	Recommendation for Medicare System Requirements

C. Interfaces: N/A

D. Contractor Financial Reporting /Workload Impact: N/A

E. Dependencies: N/A

F. Testing Considerations: N/A

IV. SCHEDULE, CONTACTS, AND FUNDING

Effective Date: July 1, 2004 **Implementation Date:** July 6, 2004 **Pre-Implementation Contact(s):** Appropriate regional office **Post-Implementation Contact(s):** Appropriate regional office	**These instructions shall be implemented within your current operating budget.**